10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
PFIZER INC | |||
Ticker: PFE Fiscal Year: 2013 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2013 10-K (Filed: Feb 28, 2014) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | |
| Revenues | $ 51,584 | 54,657 | 61,035 |
| Costs and expenses: | |||
| Cost of sales(a) | 9,586 | 9,821 | 12,500 |
| Selling, informational and administrative expenses(a) | 14,355 | 15,171 | 17,581 |
| Research and development expenses(a) | 6,678 | 7,482 [1] | 8,681 |
| Amortization of intangible assets | 4,599 | 5,109 | 5,465 |
| Restructuring charges and certain acquisition-related costs | 1,182 | 1,810 [2] | 2,841 |
| Other (income)/deductionsnet | (532) | 4,022 | 2,486 |
| Income from continuing operations before provision for taxes on income | 15,716 | 11,242 | 11,481 [3] |
| Provision for taxes on income | 4,306 | 2,221 | 3,621 |
| Income from continuing operations | 11,410 | 9,021 | 7,860 |
| Discontinued operations: | |||
| Income from discontinued operationsnet of tax | 308 | 794 | 885 |
| Gain on disposal of discontinued operationsnet of tax | 10,354 | 4,783 | 1,304 |
| Discontinued operationsnet of tax | 10,662 | 5,577 | 2,189 |
| Net income before allocation to noncontrolling interests | 22,072 | 14,598 | 10,049 |
| Less: Net income attributable to noncontrolling interests | 69 | 28 | 40 |
| Net income attributable to Pfizer Inc. | 22,003 | 14,570 | 10,009 |
| Earnings per common sharebasic: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders | 1.67 | 1.21 | 1.00 |
| Discontinued operationsnet of tax | 1.56 | 0.75 | 0.28 |
| Net income attributable to Pfizer Inc. common shareholders | 3.23 | 1.96 | 1.28 |
| Earnings per common sharediluted: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders | 1.65 | 1.20 | 0.99 |
| Discontinued operationsnet of tax | 1.54 | 0.74 | 0.28 |
| Net income attributable to Pfizer Inc. common shareholders | 3.19 | 1.94 | 1.27 |
| Weighted-average sharesbasic | 6,813 | 7,442 | 7,817 |
| Weighted-average sharesdiluted | 6,895 | 7,508 | 7,870 |
| Cash dividends paid per common share | 0.96 | 0.88 | 0.80 |
| [1] Exclusive of amortization of intangible assets, except as disclosed in Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets. | |||
| [2] Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. | |||
| [3] 2013 v. 2012The decrease in the domestic loss was primarily due to income from a litigation settlement in the second quarter of 2013 with Teva and Sun for patent-infringement damages resulting from their at-risk launches of generic Protonix in the U.S., lower charges related to other legal matters, lower restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives, partially offset by lower revenues. The increase in international income is primarily rela | |||
| External Links | |
| PFIZER INC (PFE) Fiscal Year 2013 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |